A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Silence Therapeutics plc operates in the Pharmaceutical Preparations industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 43M | 43M | 32M |
| Net Income | -45M | -45M | -54M |
| EPS | $-0.33 | $-0.33 | $-0.49 |
| Free Cash Flow | -68M | -68M | -50M |
| ROIC | -37.3% | -33.8% | -231.3% |
| Gross Margin | 72.7% | 72.7% | 59.3% |
| Debt/Equity | 0.00 | 0.51 | 4.43 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -63M | -63M | -64M |
| Operating Margin | -146.4% | -146.4% | -203.5% |
| ROE | -33.8% | -58.1% | -246.6% |
| Shares Outstanding | 137M | 137M | 111M |
| Metric | 2023 | ||
|---|---|---|---|
| Income Statement | |||
| Revenue | 32M | 43M | 43M |
| Gross Margin | 59.3% | 72.7% | 72.7% |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -64M | -63M | -63M |
| Op. Margin | -203.5% | -146.4% | -146.4% |
| Net Income | -54M | -45M | -45M |
| Net Margin | -171.4% | -104.7% | -104.7% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | N/M | -33.8% | -37.3% |
| ROE | -246.6% | -58.1% | -33.8% |
| ROA | -45.4% | -28.1% | -22.4% |
| Cash Flow | |||
| Op. Cash Flow | -49M | -68M | -68M |
| Free Cash Flow | -50M | -68M | -68M |
| Owner Earnings | -66M | -84M | -84M |
| CapEx | 56K | 211K | 211K |
| Maint. CapEx | 369K | 336K | 336K |
| Growth CapEx | 0 | 0 | 0 |
| D&A | 369K | 336K | 336K |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 16M | 16M | 16M |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | N/A | N/A | 0 |
| Cash & Equiv. | N/A | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A |
| Debt/Equity | 4.43 | 0.51 | 0.00 |
| Interest Coverage | N/A | N/A | N/A |
| Equity | 22M | 134M | 134M |
| Total Assets | 119M | 203M | 203M |
| Total Liabilities | 97M | 69M | 69M |
| Intangibles | 10.0M | 9.4M | 9.4M |
| Retained Earnings | -432M | -474M | -474M |
| Working Capital | 81M | 171M | 171M |
| Current Assets | 103M | 187M | 187M |
| Current Liabilities | 22M | 17M | 17M |
| Per Share Data | |||
| EPS | -0.49 | -0.33 | -0.33 |
| Owner EPS | -0.60 | -0.61 | -0.61 |
| Book Value | 0.20 | 0.98 | 0.98 |
| Cash Flow/Share | -0.45 | -0.49 | -0.33 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 110.7M | 137.3M | 137.3M |
| Valuation | |||
| P/E Ratio | N/A | N/A | -7.3 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | 7.5 | 2.3 | 2.5 |
| Price/Sales | 5.9 | 18.0 | 7.6 |
| FCF Yield | -29.8% | -22.0% | -20.6% |
| Market Cap | 166M | 309M | 330M |
| Avg. Price | 1.70 | 5.68 | 2.40 |
| Year-End Price | 1.50 | 2.25 | 2.40 |
Silence Therapeutics plc passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 66.0%.
Silence Therapeutics plc (SLNCF) has a 5-year average return on invested capital (ROIC) of -33.8%. This is below average and may indicate limited pricing power.
Silence Therapeutics plc (SLNCF) has a market capitalization of $330M. It is classified as a small-cap stock.
Silence Therapeutics plc (SLNCF) does not currently pay a regular dividend.
Silence Therapeutics plc (SLNCF) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Silence Therapeutics plc (SLNCF) reported annual revenue of $43 million in its most recent fiscal year, based on SEC EDGAR filings.
Silence Therapeutics plc (SLNCF) has a net profit margin of -104.7%. The company is currently unprofitable.
Silence Therapeutics plc (SLNCF) generated $-68 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Silence Therapeutics plc (SLNCF) has a debt-to-equity ratio of 0.51. This indicates moderate leverage.
Silence Therapeutics plc (SLNCF) reported earnings per share (EPS) of $-0.33 in its most recent fiscal year.
Silence Therapeutics plc (SLNCF) has a return on equity (ROE) of -58.1%. A negative ROE may indicate losses or negative equity.
Silence Therapeutics plc (SLNCF) has a 5-year average gross margin of 66.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 2 years of financial data for Silence Therapeutics plc (SLNCF), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Silence Therapeutics plc (SLNCF) has a book value per share of $0.98, based on its most recent annual SEC filing.